- Home
- CAI vs RYTM Comparison
CAI vs RYTM Comparison
Compare CAI & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAI | RYTM |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | United States |
| Employees | 1846 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.8B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CAI | RYTM |
|---|---|---|
| Price | $17.31 | $114.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $30.91 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 2.8M | 992.6K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.24 | $55.34 |
| Revenue Next Year | $22.32 | $86.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.19 | $74.50 |
| 52 Week High | $42.50 | $122.20 |
Technical Indicators
Market Signals| Indicator | CAI | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 45.60 | 71.54 |
| Support Level | $14.19 | $98.30 |
| Resistance Level | $19.83 | $122.20 |
| Average True Range (ATR) | 1.16 | 4.86 |
| MACD | -0.10 | 0.94 |
| Stochastic Oscillator | 11.11 | 91.15 |
Price Performance
Historical ComparisonAbout CAI Caris Life Sciences Inc.
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.